Skip to main content

Shorts are gettin' busy

Short interest is up by...hold for it...588% since the beginning of the year. 


If you don't believe me, check my math from the NASDAQ table below. Total short shares was 1.65 in January, and last report is coming in at 11.4m shares. That's about a 7 fold increase in shorty has made...betting against us for the last 11 months.

Ok, now, so what??

What this means is that in the short run, we might are and may continue to be facing rough seas. Get ready to throw up every day or two.  We lost nearly 30% over the last 30 days (today we're up, thank God), but things are rocky...just in case you haven't noticed.  And given the massive, 7 fold increase in short interest, they might stay rocky....or just go down (like they have taken ADXS down to 3...from 8).  Let me say that again. We might actually see AUPH at 3, in the short term, because shorty wants to bring us down, down down - and the 11.4 MILLION short shares are evidence of that. So, set your expectations. The short term might really, really suck.

But then, why are you here?  If you're here for a quick return, a company sale in the next 3 months at 25...STOP READING THIS BLOG AND SELL!!  Seriously, this is a long game. We've only just started a Phase III trial, so there are no products for sale. There's no information coming out anytime soon. There are just games - and these games are excruciating, just terrifying if you have a large portion of your unbalanced portfolio in AUPH.  Long term, well, that's another story. It does look like Voclosporin is going to work for a bunch of indications, and it's not crazy to expect the company to get sold at 50 (I've run these numbers and posted them publicly).

So ask yourself - do you mind being seasick for a year, or more?

GLTA

TC


10/31/201711,398,7451,861,0506.124900


1/13/20171,654,835968,9651.707838

Comments

  1. pwqNovember 20, 2017 at 5:47 AM

    It feels as though your confidence is shook. And that scares me more than the shorts.

    ReplyDelete
    Replies
    1. Trading CyclistNovember 20, 2017 at 5:56 AM

      My confidence has not been shaken, except for the short term. I'm just trying to set realistic expectations for the next 12 months so I hang on for the ride. This is going to take some time.

      Delete
  2. NeilNovember 21, 2017 at 1:27 PM

    12 months from now we should have FSGS/MCD interim P2 data, P2 VOS tolerability data (and hopefully monetization of that asset or plan for same) and initiation of rolling NDA for voclosporin for LN.

    I would say that we have many good things to look forward to in the short term. If these turn out positive, 8s in 11/18 seems a reasonable expectation to me.

    ReplyDelete

Post a Comment

Popular posts from this blog

June 6, 2017. Buy Out at 63?

Take a spin on our BO pricing model! The Trading Cyclist Our model is generating a range of $35-63 BO PPS , per the low/high case scenarios below - where only the Voc  price  is different (25 k vs 50k). My hunch is that this is both conservative and in the ballpark.  It's conservative b/c: 1) patient population is consistent with Aurinia's projection; 2) assumes only 35% of population on treatment; 3) assumes 75% discount for European market; 4) pricing is at 50% of range projected by Aurinia; 5) uses target P/S ratio of 3, which is below Biotech industry average of 5.0.  Outcome   Patient Pool  (Same for both Scenarios)  Pricing :  Price/Sales ratio   Here's the  Link to the model Low end BO PPS w/30% discount:  $35  ($50 no discount)  High End BO PPS w/30% discount  $63  ($90 no discount)  Prev: 26.5 per 100,000 (Based on epidemiological study)  Total Patient po...
25 comments
Read more

June 8, 2017: The case for early approval of Voclosporin

Voclosporin will likely be approved well before the P3 trial runs it course. Here's how it's going to work.  First, there's a legal and regulatory path for this approval .  While I quote the relevant passage below, here's the link to the  FDA Regulations , as well as  a   list of drugs   t hat received accelerated approval.  Sec. 314.510 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity. FDA may grant marketing approval for a new drug product on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoin t that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. Approval under this section will be subject to the requirement that ...
16 comments
Read more

iHub has been hijacked by trolls

Yup. iHub can't get rid of "Biotech Researcher," aka BR.  It's both a win for BR (the troll), and a huge loss for iHub. Their platform loses value and credibility when they refuse to take action on perma-trolls that derail the discussion and distract investors from their efforts to just honestly share information and opinions on the equities they own. So shame on iHub for not taking action to resolve this. I'm going to cease and desist on posting there until the troll (BR) problem has been resolved, and credible, valuable posters have been reinstated. I've already cancelled my premium membership some time ago. I suggest you do the same. With kind regards to all Trading Cyclist (aka TC)
53 comments
Read more